Pharma C Investments - Result of AGM
20/12/2022 16:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221220:nRST3763Ka&default-theme=true
RNS Number : 3763K Pharma C Investments PLC 20 December 2022
20 December 2022
Pharma C Investments PLC
("Pharma C" or the "Company")
Result of Annual General Meeting
Pharma C Investments (AQSE: PCIL), an early-stage investor and venture builder
in the medical cannabis industry with a particular focus on companies that
provide ancillary products and services to the medicinal cannabis sectors,
announces that at the Annual General Meeting of the Company ("AGM") held at 11
a.m. today, resolutions 1, 2 and 3, as set out in the notice of AGM posted to
shareholders on 24 November, were passed, and resolutions 4, 5 and 6.1 to 6.4
were rejected.
Following the AGM, Sharon Segal and Toby Shillito are therefore no longer
directors of the Company. The Company will appoint at least one other director
as soon as is practically possible.
The Director of the Company accepts responsibility for the contents of this
announcement.
This announcement contains inside information for the purposes of Article 7 of
the EU Regulation 596/2014 as it forms part of the UK law by virtue the
European Union (Withdrawal) Act 2018
For further information please visit www.pharmacinvestments.com
(http://www.pharmacinvestments.com/)
For additional information please contact:
Pharma C Investments
Gavin Sathianathan, Investment Strategy Director
gavin@pharmacinvestments.com
Novum Securities (AQSE Corporate Adviser)
Tel: +44 207 399 9400
David Coffman
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NEXFLFFRFTLIFIF